A PYMNTS Company

EU: Regulator to clear Zimmer’s $13.4 billion Biomet deal

By  |  March 18, 2015

Zimmer, US medical device maker, is set to secure conditional approval from European Union regulators for its proposed $13.4 billion takeover of rival Biomet, Reuters reported on Wednesday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Zimmer, which would become the No. 2 player in the $45 billion global orthopaedics market after the acquisition, revised its concessions to the European Commission last month, saying they were generally consistent with an earlier package.

    In December the company proposed selling one brand for partial, or unicompartmental, knee replacements and one elbow brand in Europe, as well as a knee replacement brand in two European countries.

    The EU competition authority has set a May 26 deadline for its decision.

     

    Full Content: Reuters

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.